Official Title
Longitudinal and Comparative Study of Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients
Brief Summary

Olfactory and gustatory disorders are prevalent symptoms in European COVID-19 patients. This study aimed to detect these disturbances among positive COVID-19 patients (symptom not initially highlighted by the patient and not sought by caregivers) in order to allow early management of olfactory and gustatory dysfunction.

Detailed Description

Several medical teams have recently shown that disturbances of smell and taste are common and
can be a precursor and even an isolated sign of COVID-19 involvement. Preliminary results
suggest the presence of clinical MRI abnormalities, particularly in the olfactory bulbs in
anosmic patients with COVID-19.

Anosmia and taste disturbance are early warning signs that could be important in improving
the detection and diagnosis of COVID-19, and also in monitoring disease. In addition,
disturbances in smell and taste could be an aid in establishing the prognosis of the clinical
course of the viral disease. The question of olfactory recovery is also fundamental. To date,
we do not know the possibilities of recovery from COVID-19 post viral anosmia. ENT exams,
olfactometry and MRI are proposed to study these phenomena.

Completed
Olfaction Disorders
COVID-19

Diagnostic Test: ENT exam

ENT examination of the nasal cavity: nasofibroscopy and anterior rhinoscopy.

Diagnostic Test: Olfactometry

Olfactometry test using odorous pens (Sniffin's stick test).

Diagnostic Test: Brain MRI

Brain MRI focused on the olfactory bulbs (3 teslas).

Eligibility Criteria

Inclusion Criteria:

- Patient aged 18 or over

- Patient with or without a sense of smell diagnosed with a positive COVID-19 PCR test
by nasopharyngeal swab in one of the investigation centers

- Patient who has already undergone cerebral MRI and olfactometry, as part of their
routine care, within 3 days of being diagnosed with COVID-19+ or who agrees to undergo
cerebral MRI and olfactometry within 3 days of being diagnosed with COVID-19+.

- Patient who signed a consent form

- Patient being affiliated to a Health Insurance plan

Exclusion Criteria:

- History of chronic rhino-sinusitis with or without polyp (s)

- History of major craniofacial trauma that led to loss of smell

- History of chronic sense of smell

- Diagnosis of Parkinson's disease or Alzheimer's disease

- Refusal to perform the 3 MRIs

- Refusal to participate in the study

- Pregnant, parturient or lactating woman

- Patient with contraindications to performing MRI

- Patient not speaking or understanding French

- Patient deprived of liberty or under guardianship

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Hopital Foch
Suresnes, Ile-de-France, France

Hopital Raymond Poincare
Garches, France

Hôpital Raymond Poincaré
NCT Number
Keywords
anosmia
smell disorder
Covid-19
MRI
MeSH Terms
COVID-19
Olfaction Disorders